(Q37429034)

English

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

scientific article published on April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

mutational analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

endometrial cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Kimberly K Leslie

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

6

object named as

Vicky Makker

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

author name string

Andrea P Myers

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Virginia L Filiaci

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Yuping Zhang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Michael Pearl

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Kian Behbakht

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Parviz Hanjani

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Susan Zweizig

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

James J Burke

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Gordon Downey

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Paul Van Hummelen

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Michael J Birrer

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Gini F Fleming

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

language of work or name

0 references

publication date

1 April 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

141

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

43-48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Regulation of mTORC1 by PI3K signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Cancer statistics, 2015

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Response and acquired resistance to everolimus in anaplastic thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Integrated genomic characterization of endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Genome sequencing identifies a basis for everolimus sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

A framework for variation discovery and genotyping using next-generation DNA sequencing data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

23 August 2017

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

14 September 2017

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

26 June 2018

PTEN/MMAC1 mutations in endometrial cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

26 June 2018

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

2 September 2018

Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

2 September 2018

Analysis of TSC1 truncations defines regions involved in TSC1 stability, aggregation and interaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5119517

2 September 2018

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.02.025

7 January 2021

A Method for Computing Profile-Likelihood-Based Confidence Intervals

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.02.025

7 January 2021

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.02.025

7 January 2021

β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.02.025

7 January 2021

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/27016228

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.YGYNO.2016.02.025

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

release_zzkmzmt4gfas7f6dyxo7zwxtc4

1 reference

https://api.fatcat.wiki/v0/release/zzkmzmt4gfas7f6dyxo7zwxtc4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27016228%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37429034&oldid=2086519566"